The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
On The Rate and Extent of Drug Delivery to the Brain
Open accessAbstract
To define and differentiate relevant aspects of blood-brain barrier transport and distribution in order to aid research methodology in brain drug delivery. Pharmacokinetic parameters relative to the rate and extent of brain drug delivery are described and illustrated with relevant data, with special emphasis on the unbound, pharmacologically active drug molecule. Drug delivery to the brain can be comprehensively described using three parameters: Kp,uu (concentration ratio of unbound drug in brain to blood), CLin (permeability clearance into the brain), and Vu,brain (intra-brain distribution). The permeability of the blood-brain barrier is less relevant to drug action within the CNS than the extent of drug delivery, as most drugs are administered on a continuous (repeated) basis. Kp,uu can differ between CNS-active drugs by a factor of up to 150-fold. This range is much smaller than that for log BB ratios (Kp), which can differ by up to at least 2,000-fold, or for BBB permeabilities, which span an even larger range (up to at least 20,000-fold difference). Methods that measure the three parameters Kp,uu, CLin, and Vu,brain can give clinically valuable estimates of brain drug delivery in early drug discovery programmes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
Physiological Parameters in Laboratory Animals and Humans
Davies, B., & Morris, T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018943613122 · Cited by 2,926
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Extracellular space structure revealed by diffusion analysis
Nicholson, C., & Syková, E. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01261-2 · Cited by 914
Blood-brain barrier active efflux transporters: ATP-binding cassette gene family
Löscher, W., & Potschka, H. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.86 · Cited by 872
Levin, V. A. (1980) · Journal of Medicinal Chemistry · doi:10.1021/jm00180a022 · Cited by 813
The Concept of a Blood-Brain Barrier
(1980) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(80)90073-7 · Cited by 790
Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology
Abbott, N. J. (2004) · Neurochemistry International · doi:10.1016/j.neuint.2003.11.006 · Cited by 786
Nicholson, C., & Phillips, J. M. (1981) · The Journal of Physiology · doi:10.1113/jphysiol.1981.sp013981 · Cited by 785
The ATP switch model for ABC transporters
Higgins, C. F., & Linton, K. J. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb836 · Cited by 748
Cited by
Blood–brain barrier structure and function and the challenges for CNS drug delivery
Abbott, N. J. (2013) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-013-9608-0 · Cited by 909
The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery
Smith, D. A., Di, L., & Kerns, E. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3287 · Cited by 898
The blood-brain barrier: an engineering perspective
Wong, A. D., Ye, M., Levy, A. F., Rothstein, J. D., Bergles, D. E., & Searson, P. C. (2013) · Frontiers in Neuroengineering · doi:10.3389/fneng.2013.00007 · Cited by 662
“Evidence suggests that there may be significant biochemical differences, for example in the expression levels of transporters and pumps that make the human blood-brain barrier unique (Hammarlund-Udenaes et al., 2008).”
BackgroundCNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
Rankovic, Z. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501535r · Cited by 548
Agrawal, M., Ajazuddin, Tripathi, D. K., Saraf, S., Saraf, S., Antimisiaris, S. G., Mourtas, S., Hammarlund-Udenaes, M., & Alexander, A. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.05.019 · Cited by 356
Self-citationFan, J., & de Lannoy, I. A. M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.007 · Cited by 309
Demystifying Brain Penetration in Central Nervous System Drug Discovery: Miniperspective
Di, L., Rong, H., & Feng, B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301297f · Cited by 304
Wang, J., Hodes, G. E., Zhang, H., Zhang, S., Zhao, W., Golden, S. A., Bi, W., Menard, C., Kana, V., Leboeuf, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02794-5 · Cited by 274
Raub, T. J., Wishart, G. N., Kulanthaivel, P., Staton, B. A., Ajamie, R. T., Sawada, G. A., Gelbert, L. M., Shannon, H. E., Sanchez-Martinez, C., & De Dios, A. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062745 · Cited by 284
“The unbound brain-to-unbound plasma concentration ratio (Kp,uu) was 0.03 6 0.01, consistent with active efflux limiting brain exposure (Hammarlund-Udenaes et al., 2008) (Table 5).”
BackgroundInfluentialBicker, J., Alves, G., Fortuna, A., & Falcão, A. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.03.012 · Cited by 262
Engineered human blood–brain barrier microfluidic model for vascular permeability analyses
Hajal, C., Offeddu, G. S., Shin, Y., Zhang, S., Morozova, O., Hickman, D., Knutson, C. G., & Kamm, R. D. (2022) · Nature Protocols · doi:10.1038/s41596-021-00635-w · Cited by 257
The glymphatic system: implications for drugs for central nervous system diseases
Lohela, T. J., Lilius, T. O., & Nedergaard, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00500-9 · Cited by 254
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Cummings, J., Ritter, A., & Zhong, K. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179901 · Cited by 176
Saunders, N. R., Habgood, M. D., Møllgård, K., & Dziegielewska, K. M. (2016) · F1000Research · doi:10.12688/f1000research.7378.1 · Cited by 143
Liu, X., Vilenski, O., Kwan, J., Apparsundaram, S., & Weikert, R. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.026674 · Cited by 75
Li, J., Wu, J., Bao, X., Honea, N., Xie, Y., Kim, S., Sparreboom, A., & Sanai, N. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0983 · Cited by 68
“, BBB integrity, transporter abundance/activity, cerebral blood flow, and cerebrospinal fluid bulk flow) (5-7).”
BackgroundTwo Functions, One Molecule: A Metal‐Binding and a Targeting Moiety to Combat Alzheimer's Disease
Hureau, C., Sasaki, I., Gras, E., & Faller, P. (2010) · ChemBioChem · doi:10.1002/cbic.201000102 · Cited by 49
Harati, R., Villégier, A.-S., Banks, W. A., & Mabondzo, A. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-273 · Cited by 45
Zhang, W., Oh, J.-H., Zhang, W., Rathi, S., Le, J., Talele, S., Sarkaria, J. N., & Elmquist, W. F. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03574-1 · Cited by 19
Zhang, W., Vaubel, R. A., Oh, J.-H., Mladek, A. C., Talele, S., Zhang, W., Waller, K. L., Burgenske, D. M., Sarkaria, J. N., & Elmquist, W. F. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0217 · Cited by 8
Metadata
- Authors
- Hammarlund-Udenaes, M., Fridén, M., Syvänen, S., & Gupta, A.
- Venue
- Pharmaceutical Research
- Published
- 2007-12-05
- Volume
- 25
- Issue
- 8
- Pages
- 1737-1750
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W2058780134
- Cited by
- 513
- References
- 106
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.